Celltrion Launches Remsima SC In UK
Innovative Subcutaneous Infliximab Also Receives Korean Approval
Celltrion has launched Remsima SC in the UK. Meanwhile, the innovative subcutaneous version of biosimilar infliximab has also received approval in Korea.
You may also be interested in...
Celltrion has pushed into another new market with its Remsima SC subcutaneous version of infliximab, launching the innovative biosimilar in Canada.
Celltrion has received an endorsement from the European Medicines Agency that means that its Remsima SC subcutaneous formulation of infliximab can be used directly in rheumatoid arthritis patients, without the need for intravenous loading first.
Health Canada has approved Celltrion’s subcutaneous version of Remsima for rheumatoid arthritis, as Celltrion plans to expand indications for the infliximab biosimilar to allow it to also treat inflammatory bowel disease. The company has also established an offshoot in Canada that will allow it to sell Remsima SC directly.